Moh'd Khushman, MD
Medical Oncology · Saint Louis, MONPI 1750546735
Payments from drug & device makers
Across 243 payments — averaging $6366.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$496K
- AbbVie$332K
- Ipsen Bioscience Inc.$238K
- AstraZeneca$181K
- Incyte Corporation$144K
- E.r. Squibb & Sons, L.L.C.$63K
- plus $93K from 24 others
Across 2 payments — averaging $4190.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$4K
- Eli Lilly$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 60 | $495,588 |
| AbbVie | 23 | $331,870 |
| Ipsen Bioscience Inc. | 28 | $238,327 |
| AstraZeneca | 44 | $180,539 |
| Incyte Corporation | 2 | $144,275 |
| E.r. Squibb & Sons, L.L.C. | 6 | $63,291 |
| Eli Lilly | 2 | $22,143 |
| Deciphera Pharmaceuticals Inc. | 8 | $19,380 |
| Beone Medicines USA, Inc. | 2 | $15,812 |
| Array Biopharma Inc | 7 | $13,288 |
| GSK | 3 | $6,700 |
| Exelixis Inc. | 9 | $5,440 |
| Pfizer | 5 | $2,709 |
| Taiho Oncology, Inc. | 1 | $1,875 |
| Trisalus Life Sciences, Inc. | 2 | $1,212 |
| Bayer | 2 | $1,125 |
| Astrazeneca UK Limited | 9 | $1,071 |
| Caris MPI, Inc. | 3 | $829 |
| Ipsen Biopharmaceuticals, Inc | 7 | $626 |
| Novartis | 4 | $301 |
| Eisai Inc. | 4 | $181 |
| Bristol Myers Squibb | 2 | $157 |
| Tempus AI, Inc | 1 | $94 |
| Lilly USA, LLC | 1 | $86 |
| Astellas Pharma US Inc | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Genentech, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Gilead | 1 | $12 |
How this compares
$1,547,084 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Saint Louis
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Brad KahlSaint Louis$11.3M
- Russell PachynskiSaint Louis$8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.